Safety and Efficacy of an Oxytocin Gel and an Equivalent Gel but Without Hormonal Ingredients (Vagivital® Gel) in Postmenopausal Women with Symptoms of Vulvovaginal Atrophy: A Randomized, Double-Blind Controlled Study

Aino Fianu Jonasson, Marie Bixo, Inger Sundström Poromaa, Mikael Åstrom, Aino Fianu Jonasson, Marie Bixo, Inger Sundström Poromaa, Mikael Åstrom

Abstract

Purpose: The primary objective was to compare the efficacy of 12 weeks of daily treatment with Aqueous Hypromellose-based vaginal (Vagivital®) gel versus Aqueous Hypromellose-based vaginal gel plus 400 IU oxytocin gel in reducing the severity of the most bothersome vulvovaginal atrophy symptoms (MBS: itching, dysuria, bleeding, and pain/discomfort during vaginal sexual activity) observed at baseline. The secondary objectives were to evaluate the other vulvovaginal atrophy symptoms, vaginal pH, superficial squamous cells, and the safety and tolerability of both gels.

Patients and methods: This double-blind, randomized study evaluated the safety and efficacy of subjects randomly assigned to 12 weeks of daily intravaginal oxytocin gel (n=79) or Aqueous Hypromellose-based vaginal gel (n=78). The efficacy evaluation was performed using data from all included subjects who fulfilled entry criteria.

Results: Both treatments induced statistically significant reductions in the severity of the MBS from baseline until 4 weeks (Vagivital mean reduction 0.90, p=0.0000; Oxytocin mean reduction 0.82, p=0.0000) and 12 weeks post baseline (Vagivital mean reduction 1.28, p=0.0000; Oxytocin mean reduction 1.16, p=0.0000), but the reduction of MBS severity was not significantly different between the treatment groups at either time point. No serious adverse events were reported in the Aqueous Hypromellose-based vaginal gel group during the treatment period, but one (breast cancer) was reported in the oxytocin gel group (assessed as unlikely related to the study compound).

Conclusion: Significant reductions in the severity of the MBS were seen in both the Aqueous Hypromellose-based vaginal gel and the oxytocin gel groups, but with no significant differences in severity reduction seen between the groups. Both gels were safe and well tolerated. Given the benefits of avoiding the use of hormones, Aqueous Hypromellose-based vaginal gel is an attractive first choice in the treatment of postmenopausal women with vulvovaginal atrophy symptoms.

Keywords: MBS; dyspareunia; most bothersome vulvovaginal atrophy symptoms; non-hormonal therapy; vaginal dryness.

Conflict of interest statement

Dr Inger Sundström Poromaa reports personal fees from Peptonics, during the conduct of the study; personal fees from Bayer AB, Shire/Takeda, and Gedeon Richter, outside the submitted work. The authors report no other conflicts of interest in this work.

© 2020 Fianu Jonasson et al.

Figures

Figure 1
Figure 1
Subject disposition.

References

    1. Iosif CS, Bekassy Z. Prevalence of genito-urinary symptoms in the late menopause. Acta Obstet Gynecol Scand. 1984;63:257–260. doi:10.3109/00016348409155509
    1. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;2016:Cd001500. doi:10.1002/14651858.CD001500.pub3
    1. Henriksson L, Stjernquist M, Boquist L, Cedergren I, Selinus I. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol. 1996;174:85–92. doi:10.1016/s0002-9378(96)70378-2
    1. Caillouette JC, Sharp CF Jr, Zimmerman GJ, Roy S. Vaginal pH as a marker for bacterial pathogens and menopausal status. Am J Obstet Gynecol. 1997;176:1270–1275; discussion 1275–1277. doi:10.1016/s0002-9378(97)70345-4
    1. Bachmann GA. The clinical platform for the 17beta-estradiol vaginal releasing ring. Am J Obstet Gynecol. 1998;178:S257–S260. doi:10.1016/s0002-9378(98)70558-7
    1. Grady D. Clinical practice. Management of menopausal symptoms. N Engl J Med. 2006;355:2338–2347. doi:10.1056/NEJMcp054015
    1. Cano A, Estévez J, Usandizaga R, et al. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal Phase III study. Menopause. 2012;19:1130–1139. doi:10.1097/gme.0b013e3182518e9a
    1. Freedman M, Kaunitz AM, Reape KZ, Hait H, Shu H. Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy. Menopause. 2009;16:735–741. doi:10.1097/gme.0b013e318199e734
    1. Fernandes T, Costa-Paiva LH, Pedro AO, Baccaro LFC, Pinto-Neto AM. Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on vaginal atrophy: a randomized controlled trial. Menopause. 2016;23(7):792–798. doi:10.1097/gme.0000000000000613
    1. Kallak TK, Uvnäs-Moberg K. Oxytocin stimulates cell proliferation in vaginal cell line Vk2E6E7. Post Reprod Health. 2017;23:6–12. doi:10.1177/2053369117693148
    1. Uvnas-Moberg K, Petersson M. [Oxytocin, a mediator of anti-stress, well-being, social interaction, growth and healing] [Original text in German]. Z Psychosom Med Psychother. 2005;51:57–80. doi:10.13109/zptm.2005.51.1.57
    1. Al-Saqi SH, Jonasson AF, Naessén T, Uvnäs-Moberg K. Oxytocin improves cytological and histological profiles of vaginal atrophy in postmenopausal women. Post Reprod Health. 2016;22:25–33. doi:10.1177/2053369116629042
    1. Al-Saqi SH, Uvnäs-Moberg K, Jonasson AF. Intravaginally applied oxytocin improves post-menopausal vaginal atrophy. Post Reprod Health. 2015;21:88–97. doi:10.1177/2053369115577328
    1. Torky HA, Taha A, Marie H, et al. Role of topical oxytocin in improving vaginal atrophy in postmenopausal women: a randomized, controlled trial. Climacteric. 2018;21:174–178. doi:10.1080/13697137.2017.1421924
    1. Ghorbani Z, Mirghafourvand M. The efficacy and safety of intravaginal oxytocin on vaginal atrophy: A systematic review. Post Reprod Health. 2020;2053369120946645. doi:10.1177/2053369120946645.
    1. Society NAM. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20:888–902; quiz 903–884. doi:10.1097/GME.0b013e3182a122c2
    1. 1177 Vårdguiden. Klimakteriebesvär [Health Care Guide. Menopausal Symptoms]; 2017. Available from: . Accessed January12, 2018.
    1. Ayehunie S, Wang YY, Landry T, Bogojevic S, Cone RA. Hyperosmolal vaginal lubricants markedly reduce epithelial barrier properties in a three-dimensional vaginal epithelium model. Toxicol Rep. 2018;5:134–140. doi:10.1016/j.toxrep.2017.12.011
    1. Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2016;19:151–161. doi:10.3109/13697137.2015.1124259
    1. Lima SM, Bernardo BFA, Yamada SS, et al. Effects of Glycine max (L.) Merr. soy isoflavone vaginal gel on epithelium morphology and estrogen receptor expression in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled trial. Maturitas. 2014;78(3):205–211. doi:10.1016/j.maturitas.2014.04.007
    1. Jokar A, Davari T, Asadi N, Ahmadi F, Foruhari S. Comparison of the hyaluronic acid vaginal cream and conjugated estrogen used in treatment of vaginal atrophy of menopause women: a randomized controlled clinical trial. Int J Community Based Nurs Midwifery. 2016;4:69–78.
    1. Lima SMRR, Yamada SS, Reis BF, et al. Effective treatment of vaginal atrophy with isoflavone vaginal gel. Maturitas. 2013;74(3):252–258. doi:10.1016/j.maturitas.2012.11.012
    1. Vagifem. Vagifem® (estradiol vaginal inserts) 10 mcg; 2017. Available from: . Accessed July18, 2017.
    1. Vagitocin [Investigator’s Brochure] Edition 7.0.; Peptonic Medical. March 2016.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe